Evoke Pharma appoints Greg Pyszcymuka to board as Class I director

Evoke Pharma Inc

Appointed effective Feb 20, 2025; term expires at 2026 annual meeting.
He is CCO of Aytu Biopharma (Nasdaq: AYTU); appointed under Nantahala Capital Management agreement (Sept 2024).
Received options for 5,833 shares vesting equally over three years; also standard cash compensation.
Compensation Committee: Hill (chair), Pyszcymuka, Brady; Nominating & Governance: Pyszcymuka, Widder, Hill (chair).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Greg Pyszcymuka

Class I director

Evoke Pharma Inc

Effective: 2025-02-20
Filed: February 24, 2025, 6:59 PM ET

On February 20, 2025, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Greg Pyszcymuka to serve as a Class I director, effective immediately, with an initial term expiring at the Company’s 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Greg Pyszcymuka was appointed as Class I director at Evoke Pharma Inc.

Action: appointed
Role: Class I director

Exact text from the filing

On February 20, 2025, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Greg Pyszcymuka to serve as a Class I director, effective immediately, with an initial term expiring at the Company’s 2026 annual meeting of stockholders.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-25-025241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.